Literature DB >> 15348250

The effects of osteoprotegerin on the mechanical properties of rat bone.

A B Ross1, T A Bateman, P J Kostenuik, V L Ferguson, D L Lacey, C R Dunstan, S J Simske.   

Abstract

Osteoprotegerin (OPG) is a naturally secreted protein that decreases bone resorption by inhibiting osteoclast differentiation and activation while promoting osteoclast apoptosis [8]. In this study, the effects of osteoprotegerin injections on long bone mechanical and material properties were investigated in young male Sprague-Dawley rats. OPG increased fracture strength at the femur mid-diaphysis in three-point bending by 30%, without affecting the elastic or maximum strength. At the femoral neck, OPG significantly increased the elastic (45%), maximum (15%), and fracture (35%) strengths. There was not a difference in microhardness at the femur mid-diaphysis in comparing the placebo and OPG groups. There were, however, significant increases in whole bone dry mass (25%), mineral mass (30%), organic mass (17%), and percent mineralization (4%); percent mineralization at the mid-diaphysis (3%); and percent mineralization at the distal epiphysis (6%) due to the OPG treatment. While OPG decreased endocortical bone formation (52%), total bone area, endocortical bone area, and periosteal bone formation were maintained with OPG treatment. A 30% increase in the X-ray opacity of the bone at the proximal metaphysis of the right tibiae was observed. Overall, OPG increased mineralization and strength indices in the rat femur. Its effects on strength were more pronounced in the femoral neck than at the mid-diaphysis. Copyright 2001 Kluwer Academic Publishers

Entities:  

Year:  2001        PMID: 15348250     DOI: 10.1023/a:1011229324412

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  10 in total

1.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

2.  Osteoprotegerin mitigates tail suspension-induced osteopenia.

Authors:  T A Bateman; C R Dunstan; V L Ferguson; D L Lacey; R A Ayers; S J Simske
Journal:  Bone       Date:  2000-05       Impact factor: 4.398

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

Review 5.  Basic biomechanical measurements of bone: a tutorial.

Authors:  C H Turner; D B Burr
Journal:  Bone       Date:  1993 Jul-Aug       Impact factor: 4.398

6.  Effects of rehydration state on the flexural properties of whole mouse long bones.

Authors:  J J Broz; S J Simske; A R Greenberg; M W Luttges
Journal:  J Biomech Eng       Date:  1993-11       Impact factor: 2.097

7.  A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

Authors:  S Morony; C Capparelli; R Lee; G Shimamoto; T Boone; D L Lacey; C R Dunstan
Journal:  J Bone Miner Res       Date:  1999-09       Impact factor: 6.741

8.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.

Authors:  M Yamamoto; T Murakami; M Nishikawa; E Tsuda; S Mochizuki; K Higashio; T Akatsu; K Motoyoshi; N Nagata
Journal:  Endocrinology       Date:  1998-09       Impact factor: 4.736

10.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

  10 in total
  8 in total

1.  The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys.

Authors:  M S Ominsky; P J Kostenuik; P Cranmer; S Y Smith; J E Atkinson
Journal:  Osteoporos Int       Date:  2007-03-24       Impact factor: 4.507

2.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

3.  Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip.

Authors:  Elizabeth J Samelson; Kerry E Broe; Serkalem Demissie; Thomas J Beck; David Karasik; Sekar Kathiresan; Douglas P Kiel
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 4.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

5.  Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drug Healthc Patient Saf       Date:  2011-12-01

Review 6.  Clinical utility of denosumab for treatment of bone loss in men and women.

Authors:  Robert A Adler; Ranjodh S Gill
Journal:  Clin Interv Aging       Date:  2011-05-24       Impact factor: 4.458

7.  Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.

Authors:  David W Dempster; Jacques P Brown; Astrid Fahrleitner-Pammer; David Kendler; Sebastien Rizzo; Ivo Valter; Rachel B Wagman; Xiang Yin; Susan V Yue; Georges Boivin
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

8.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.